5470-06-4 Usage
Uses
Used in Pharmaceutical Industry:
4-(2,5-Dioxopyrrolidin-1-yl)benzenesulfonamide is used as a diuretic and antihypertensive medication for its ability to inhibit the enzyme carbonic anhydrase, leading to decreased reabsorption of sodium and water, and resulting in increased urine production and reduced fluid retention.
Used in Cancer Research:
4-(2,5-Dioxopyrrolidin-1-yl)benzenesulfonamide is being investigated for its potential anti-cancer properties, as it has been shown to inhibit the growth of tumor cells in some studies.
Used in Ophthalmology:
4-(2,5-Dioxopyrrolidin-1-yl)benzenesulfonamide has been used in the treatment of glaucoma, where its diuretic properties can help reduce intraocular pressure.
Used in Neurology:
4-(2,5-Dioxopyrrolidin-1-yl)benzenesulfonamide is used in the treatment of epilepsy, where its effects on carbonic anhydrase may contribute to seizure control.
Used in Altitude Sickness Treatment:
4-(2,5-Dioxopyrrolidin-1-yl)benzenesulfonamide is used in the treatment of altitude sickness, where its diuretic and antihypertensive properties can help alleviate symptoms associated with high-altitude conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 5470-06-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,4,7 and 0 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 5470-06:
(6*5)+(5*4)+(4*7)+(3*0)+(2*0)+(1*6)=84
84 % 10 = 4
So 5470-06-4 is a valid CAS Registry Number.
InChI:InChI=1/C10H10N2O4S/c11-17(15,16)8-3-1-7(2-4-8)12-9(13)5-6-10(12)14/h1-4H,5-6H2,(H2,11,15,16)
5470-06-4Relevant academic research and scientific papers
Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Part 2
Al-Suwaidan, Ibrahim A.,Alanazi, Amer M.,El-Azab, Adel S.,Al-Obaid, Abdulrahman M.,Eltahir, Kamal E.H.,Maarouf, Azza R.,Abu El-Enin, Mohamed A.,Abdel-Aziz, Alaa A.-M.
, p. 2601 - 2605 (2013/06/27)
A group of cyclic imides (1-10) was designed for evaluation as a selective COX-2 inhibitors and investigated in vivo for their anti-inflammatory activity. Compounds 6a, 6b, 8a, 8b, 9a, 9b, 10a and 10b were proved to be potent COX-2 inhibitors with IC50 range of 0.1-4.0 μM. In vitro COX-1/COX-2 inhibition structure-activity studies identified compound 8a as a highly potent (IC50 = 0.1 μM), and an extremely selective [COX-2 (SI) > 1000] comparable to celecoxib [COX-2 (SI) > 384], COX-2 inhibitor that showed superior anti-inflammatory activity (ED50 = 72.4 mg/kg) relative to diclofenac (ED50 = 114 mg/kg). Molecular modeling was carried out through docking the designed compounds into the COX-2 binding site to predict if these compounds have analogous binding mode to the COX-2 inhibitors. The study showed that the homosulfonamide fragment of 8a inserted deep inside the 2 -pocket of the COX-2 active site, where the SO2NH2 group underwent H-bonding interaction with Gln192(2.95 A?), Phe 518(2.82 A?) and Arg513(2.63 and 2.73 A?). Docking study of the synthesized compound 8a into the active site of COX-2 revealed a similar binding mode to SC-558, a selective COX-2 inhibitor.
